We have celebrated the 20th anniversary of the first percutaneous transluminal coronary angioplasty (PTCA) by Grüntzig. We have seen many eVorts to render PTCA simpler and safer. While technological progresses have allowed us to approach ever more complex coronary lesions, there has been a tremendous eVort to optimise medical treatment as an adjunct to mechanical dilatation of coronary lesions. A variety of anticoagulant and antiplatelet agents have been used from the beginning to minimise the risk of abrupt coronary occlusion during and after PTCA.
Various studies have shown that heparin and aspirin significantly reduce the incidence of acute ischaemic complications of PTCA. Other antiplatelet and antithrombotic agents have been used for the same purpose.
1 Some of the initial drugs were of little help or even harmful and they were abandoned. For example, for intracoronary stents periprocedural anticoagulation was initially considered essential, until objective data favoured more simple drug regimens. 2 The exact dose of heparin needed during coronary interventions and the length of postprocedural heparin infusion is not yet established. Pretreatment with heparin in patients with intracoronary thrombus and unstable angina has reduced the incidence of acute ischaemic complications. 3 In many centres, an initial bolus of 10 000-15 000 units of heparin and further boluses to achieve activated clotting times (ACT) of over 300 seconds are routine. Yet, there is no evidence of a solid correlation between a given ACT and the risk of acute coronary occlusion. The recommended threshold of 300 seconds is an arbitrary cut oV largely based on analyses performed in patients during cardiopulmonary bypass. Narins et al recently found an inverse correlation between the level of anticoagulation (measured by ACT) and the occurrence of acute ischaemic periprocedural complications in patients undergoing PTCA. 4 In contrast, several randomised studies have suggested eYcacy and safety of low dose heparin during elective PTCA procedures, independent of ACT. 5 6 Higher doses of anticoagulants increase the risk of bleeding, which has to be considered when assessing the net advantage of intensive anticoagulation over low dose heparin in the setting of routine coronary interventions.
Abrupt vessel closure during PTCA may be an infrequent event; however, it carries a considerable risk for the patient. 7 The mechanisms of acute vessel closure are multiple and include plaque disruption, intimal dissection, coronary spasm, subintimal haemorrhage, and thrombus formation. Plaque rupture (spontaneous or by PTCA) exposes the thrombogenic subendothelial layers to platelets and coagulation proteins. Activation of platelets and the coagulation cascade are the fundamental mechanisms of arterial thrombosis, and are closely linked. Thrombin generated by blood coagulation is a potent platelet activator, and activated platelets potentiate the process of coagulation. Depending on flow conditions, there are diVerences between arterial and venous thrombi in their relative composition of fibrin and platelets. 8 Arterial thrombi form even under high flow conditions and are composed mainly of platelet aggregates bound together by thin fibrin strands (white thrombus). Venous thrombi are rich in fibrin and red blood cells and contain relatively few platelets (red thrombus). The important role of platelet activation in thrombus formation during PTCA was confirmed by several animal models and human studies. 9 10 In the past few years, more eVective platelet blockade has gained interest in the quest to decrease thrombotic complications during and after PTCA. The development and clinical use of specific glycoprotein (GP) IIb/IIIa antagonists in high risk PTCA procedures resulted in a significant reduction of acute ischaemic complications. Recent randomised trials with GP IIb/IIIa antagonists have shown best eYcacy and safety in conjunction with weight adjusted low dose heparin (about 5000 units) in terms of both ischaemic and bleeding complications. 11 In the EPIC trial, high risk patients having PTCA, including many with unstable angina, were randomly assigned to receive a GP IIb/IIIa antagonist (abciximab) or placebo in addition to full dose heparin. The incidence of major cardiac complications was significantly higher in the placebo group but full heparinisation proved a problem in conjunction with abciximab. 12 This supports starting routine coronary interventions with 5000 units of heparin, not to preclude the use of these agents if indicated. The alternative, to neutralise part of the heparin before adding a GP IIb/IIIa antagonist, is less appealing.
Koch and colleages 13 corroborated the hypothesis that low dose heparin with "suboptimal" anticoagulation during routine PTCA procedures has no adverse eVect on the outcome of patients.
14 They analysed a large number of patients representing over 75% of the population of a busy catheterisation laboratory. In almost 90% of this population, a 5000 unit bolus of heparin in addition to aspirin was the sole anticoagulant regimen. Whether the use of ioxaglate, which has been shown to have some anticoagulant eVect, 15 further reduced thrombotic complications is unclear. The ACTs in 50 patients after the administration of 5000 units of heparin were largely below the safety threshold reported in the literature. Nevertheless, the ischaemic complications remained in an acceptable range supporting the evidence that a low ACT does not predispose to abrupt closure. Bailout stenting was used in only 1.3% of the patients, which is far below current practice. It is possible that with more liberal use of intracoronary stents to optimise the angiographic results of PTCA, acute and subacute closures can be reduced further even under low dose heparinisation. 5 6 In Koch et al's study, 123 patients (9%) were given prolonged postintervention heparin; however, 45 of them still had acute ischaemic complications. Whether prolonged postprocedure heparin prevents or just postpones acute closure has been the issue of iterative debate. Recently published randomised trials have failed to show any significant beneficial eVect of prolonged heparin after uncomplicated coronary interventions. 16 The incidence of puncture site complications in patients with prolonged heparin infusion, however, was three times that of patients with a single bolus of heparin.
Low dose single bolus heparin makes particular sense if early sheath removal is performed. This also means enhanced patient comfort, short hospital stay, and reduced cost. Low dose heparin for routine PTCA can be considered a safe and established policy facilitating the use of modern potent antiplatelet agents in case of need. To think the unthinkable, we might live to see the day where heparin is completely abandoned. Plants are the origin of 36 cardiac glycosides being found in over 40 species contained within 36 genera and 11 families. The Ebers Papyrus of 1500 BC tells of the diuretic effect of the Mediterranean squill, Drimia maritima, a member of the lily family. The purple foxglove was named Digitalis from the shape of the flowers (digitus, a finger). But why "foxglove"? This is an older name and not the only one, others being fairy fingers and fairy gloves. It is said that the fairies gave the flowers to foxes to wear on their feet so that they could move in magic silence up to hens or away from men. Dr William Withering made the first scientific study of the foxglove in 1775 demonstrating its value in dropsy (oedema) but it was much later, in 1905, that Dr James Mackenzie showed that its special value was in heart failure with atrial fibrillation.
In 1930 Dr Sydney Smith isolated a new glycoside, which he called digoxin, from the Balkan or woolly foxglove Digitalis lanata. Digoxin is extracted directly from the plant, and is not synthesised. Strophanthin is present in species of the African genus Strophanthus. It belongs to the family Apocynaceae, which also contains the plants that yield the Vinca alkaloids and reserpine. It was discovered from its use as an arrow poison, not from folk medicine.
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